Highlights

  • Trajan Group (ASX:TRJ) is focused on analytical science products supporting healthcare, research and industrial applications.
  • FY26 results reflected Revenue pressure alongside improving margins and operational efficiency gains.
  • Project Neptune has supported cost reduction and Business simplification initiatives.
  • Future performance will depend on revenue recovery, Margin expansion and improved market conditions.

Trajan Group (ASX:TRJ) continues working through a business reset aimed at improving profitability and strengthening its position in the analytical science sector. The Victorian-based company supplies scientific instruments, consumables and related technologies used across healthcare, environmental and industrial applications.

The company’s FY26 performance highlighted a period of transition, with lower revenue offset by improving margins and operational efficiency initiatives designed to support future Earnings growth.

As on 4 September 2026, Trajan Group (ASX:TRJ) was trading at AUD 0.17, unchanged on the day. The share price movement comes as investors continue assessing the company’s recovery strategy, margin improvement progress and outlook for future growth.

FY26 Performance

Trajan Group’s FY26 results reflected a challenging operating environment combined with early signs of operational improvement.

Group revenue declined 3.1% to A$161.4 million, while normalised EBITDA decreased 14.7% to A$13.2 million.

However, the second half of FY26 showed improving profitability trends. Proforma gross margin increased from 37.4% to 40.6%, while second-half normalised EBITDA reached A$8.1 million.

The improvement reflected the impact of Project Neptune, an internal efficiency program focused on reducing costs, improving operational discipline and creating a more streamlined business structure.

Management positioned FY26 as a transition year, with cost initiatives aimed at establishing a stronger foundation for future growth.

Business Overview

Trajan Group operates within the analytical science and life-sciences sector, providing products used in measurement, sample preparation and laboratory analysis.

The company’s solutions support a range of applications across healthcare, environmental testing, research and materials science.

Its global customer base provides exposure to international markets, although this also means performance can be influenced by overseas research spending, capital-equipment Investment cycles and currency movements.

During FY26, the company experienced challenges including foreign exchange impacts and softer Demand in some markets, particularly around North American capital-equipment funding.

Operational Reset

Project Neptune has been a central part of Trajan’s strategy to improve efficiency and restore profitability.

The initiative has included workforce adjustments, reduced Capital expenditure and operational improvements designed to align the cost base with current market conditions.

The second-half margin improvement suggests early benefits from these measures, although sustained earnings recovery will depend on the company’s ability to combine efficiency gains with renewed revenue growth.

The company has also highlighted improving order-book conditions, which could provide support if market demand continues recovering.

Investor Considerations

Trajan Group’s investment case is based on its ability to transition from a period of earnings pressure towards sustainable growth.

The company benefits from exposure to specialised analytical science markets, where its products support important laboratory and research functions. However, revenue growth remains a key challenge after a decline during FY26.

Investors will continue monitoring whether margin improvements can be maintained and whether operational efficiencies translate into stronger cash generation.

As a globally exposed business, Trajan remains sensitive to foreign exchange movements, research funding cycles and customer investment decisions.

The company’s ability to execute its recovery plan while rebuilding top-line growth will be central to its long-term outlook.

Growth Outlook

Management has outlined expectations for mid-single-digit organic revenue growth and double-digit EBITDA growth in FY27.

Achieving these targets will depend on several factors, including continued margin improvement, recovery in customer demand and successful conversion of its order pipeline.

Key developments to monitor include North American capital-equipment demand, further benefits from Project Neptune and progress towards improving profitability.

The FY27 half-year performance will provide an important indication of whether the company’s recovery strategy is progressing as planned.

Conclusion

Trajan Group (ASX:TRJ) is navigating a transition period focused on improving efficiency, rebuilding margins and restoring earnings growth. While FY26 reflected revenue pressure and lower profitability, the company showed encouraging improvement in second-half margins.

The next phase will depend on whether these operational gains can be combined with renewed revenue growth. With its specialised analytical science offering and efficiency initiatives underway, Trajan’s ability to deliver against FY27 objectives will remain the key focus for investors.